Market Overview

Sterne Agee Adjusts Estimates For Salix Pharmaceuticals


In a report published Friday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating and $162.00 price target on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP).

In the report, Sterne Agee noted, “2Q14 results were lower than expected due to continued inventory shifts as Salix integrates Santarus, and lower EPS versus consensus was driven by increased share count. Due to this and new 3Q/FY14 guidance our 3Q14E, 4Q14E, and 2014E EPS go to $1.53, $1.95, and $6.16, from $1.69, $1.85, and $6.24, respectively, on revenues of $395.9mn, $437.6mn, and $1,599.8mn from $418.8mn, $427.6mn, and $1,626mn, respectively. Our PT remains $162.”

Salix Pharmaceuticals closed on Thursday at $133.55.

Latest Ratings for SLXP

Mar 2015DowngradesBuyHold
Feb 2015DowngradesBuyHold
Feb 2015DowngradesBuyNeutral

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings

Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Reiteration Analyst Ratings


Related Articles (SLXP)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at